524 related articles for article (PubMed ID: 2460064)
1. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
3. [Prostatic adenocarcinoma with neuroendocrine differentiation of the small cell type].
Rimoldi DA; Antonio Costa J; Roveto S; Rivero O
Medicina (B Aires); 2001; 61(3):322-4. PubMed ID: 11474882
[TBL] [Abstract][Full Text] [Related]
4. Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma.
Liu Y; Sturgis CD; Grzybicki DM; Jasnosz KM; Olson PR; Tong M; Dabbs DD; Raab SS; Silverman JF
Mod Pathol; 2001 Sep; 14(9):880-5. PubMed ID: 11557784
[TBL] [Abstract][Full Text] [Related]
5. A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines.
Jensen SM; Gazdar AF; Cuttitta F; Russell EK; Linnoila RI
Cancer Res; 1990 Sep; 50(18):6068-74. PubMed ID: 2168288
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.
Graziano SL; Tatum AH; Newman NB; Oler A; Kohman LJ; Veit LJ; Gamble GP; Coleman MJ; Barmada S; O'Lear S
Cancer Res; 1994 Jun; 54(11):2908-13. PubMed ID: 8187076
[TBL] [Abstract][Full Text] [Related]
7. Serum calcitonin in small cell carcinoma of the prostate.
Sim SJ; Glassman AB; Ro JY; Lee JJ; Logothetis CJ; Liu FJ
Ann Clin Lab Sci; 1996; 26(6):487-95. PubMed ID: 8908318
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
9. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical identification of neuron-specific enolase, synaptophysin, chromogranin and endocrine granule constituent in neuroendocrine tumours.
Vyberg M; Horn T; Francis D; Askaa J
Acta Histochem Suppl; 1990; 38():179-81. PubMed ID: 1964227
[TBL] [Abstract][Full Text] [Related]
11. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
12. Divergent neuroendocrine differentiation in prostatic carcinoma.
di Sant' Agnese PA
Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in prostatic malignancy.
di Sant'Agnese PA; Cockett AT
Cancer; 1996 Jul; 78(2):357-61. PubMed ID: 8674017
[TBL] [Abstract][Full Text] [Related]
14. [Synaptophysin, chromogranin A and neuron-specific enolase as tumor markers in neuroendocrine tumors of the gastrointestinal tract and lung. An immunohistochemical study].
Eberlein-Gonska M; Wiedenmann B; Waldherr R
Pathologe; 1989 Jul; 10(4):228-33. PubMed ID: 2549534
[No Abstract] [Full Text] [Related]
15. Small cell carcinoma of the stomach: a clinicopathologic study of 17 cases.
Matsui K; Kitagawa M; Miwa A; Kuroda Y; Tsuji M
Am J Gastroenterol; 1991 Sep; 86(9):1167-75. PubMed ID: 1715667
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in extrahepatic bile duct carcinomas and its prognostic significance.
Hong SM; Kim MJ; Pi DY; Jo D; Yu E; Ro JY
Hum Pathol; 2005 Jul; 36(7):732-40. PubMed ID: 16084941
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
20. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
Yu DS; Hsieh DS; Chen HI; Chang SY
J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
